Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 1998

View Archived Issues

Company Profile: Cell Genesys

Antidepressant properties of flibanserin may involve dopamine D2/D3 receptors

Genetronics announces end of year summary

Interneuron: Q1 1998 highlights

PKC inhibitors described by Lilly

Abbott reveals new motilides

Novel NK1 antagonists described by Merck & Co.

Progen: Annual Report 1997

Maxamine progresses to phase III in AML

Chloride channel blockers useful for sickle cell anemia

Ganaxolone demonstrates efficacy in phase II migraine trial

Pharmacia & Upjohn develops new antiproliferative agents

SKB evaluates RF-1 as antibacterial target

Nucleoside analogues from BioChem Therapeutic show potential for HIV/AIDS

Rifaximin receives orphan drug status in hepatic encephalopathy

First phase II results reported for EuroAlliance's DAAID

Patent coverage for Idec's humanized antibody for SLE

Idec RSV antibodies covered by U.S. patents; development partners sought

In vitro study shows COX-1/COX-2 inhibition not associated with anticancer activity

HFE: a new therapeutic target for iron overload disorders and cancer

Controlled trial of peptide T for cognitive impairment in HIV-infected patients

TAU-284 awaiting approval in Japan

Clinical status of CS-834

Encouraging results obtained with Hycamtin in multiple myeloma

Cor Therapeutics receives milestone for Integrilin MAA review

Reduction in brain damage with YM-872 in cat model of focal cerebral ischemia

Excellent anxiolytic/side effect profile described for LY-354740

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...